CHIEF MEDICAL OFFICER · Enliven Therapeutics, Inc. · Common Stock
Side
SELL
Value
$117K
Shares
2,441
Price
$48.06
Executed
Apr 17, 2026
Disclosed
Apr 21, 2026
Disclosure timeline4 days from execution to publication · legal deadline 2 business days
Apr 17 executedApr 21, 2026 disclosed
ELVN · daily
Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Disclosed 2 business days after execution (deadline: 2)
Historical behavior+4 / 15
1 prior trade recorded in this security
Frequency & clustering0 / 15
No clustered activity in the dataset
Market events0 / 10
No material company filing within 60 days after the trade
Pre-arranged plan-10
Executed under a Rule 10b5-1 trading plan
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Collins Helen Louise filed this Form 4 reporting a open-market sale of ELVN on Apr 17, 2026. It became public on Apr 21, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
CHIEF MEDICAL OFFICER
Collins Helen Louisecik:0001701247
Issuer
Enliven Therapeutics, Inc.cik:0001672619
Revision history · 0
No field has changed since this record was first ingested.
